Netherlands· NL-d231b5417ba5
Imaavy 185 mg/ml concentraat voor oplossing voor infusie
A medicinal product containing nipocalimab, registered in Netherlands by Janssen-Cilag International NV.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- NIPOCALIMAB
- Manufacturer
- Janssen-Cilag International NV
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/1989
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nipocalimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesIMAAVYJanssen Biotech, Inc.
- SwitzerlandImaavy 1200 mg/6.5 ml (185 mg/ml), Konzentrat zur Herstellung einer InfusionslösungJanssen-Cilag AG
- CzechiaIMAAVYJanssen-Cilag International N.V., Beerse
- BelgiumImaavy 185 mg/mlJanssen-Cilag International
- Japanニポカリマブ（遺伝子組換え）ヤンセンファーマ
- IrelandImaavy 185 mg/mL concentrate for solution for infusionJanssen-Cilag International NV
- IcelandIMAAVYJanssen Cilag International
- SpainIMAAVY 185 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONJanssen-Cilag International N.V
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imaavy
- Liechtenstein · Imaavy
- Norway · Imaavy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4093ea8a-5402-4c87-9396-a072c94f88c2 GET /v1/drugs/4093ea8a-5402-4c87-9396-a072c94f88c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/imaavy-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134103",
"excipients": [
"ARGININEHYDROCHLORIDE, (L-)",
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"METHIONINE, (L-)",
"POLYSORBAAT 80 (E 433)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"NIPOCALIMAB"
],
"leaflet_url": null,
"authorised_at": "2025/11/28",
"procedure_number": "EMEA/H/C/006379",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/1989",
"additional_monitoring": "Y"
}See everything about nipocalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.